No Serotonin-Depression Link? TMS OK’d for Anxious Depression; Phase III Win in AUD?July 21, 2022
Are low serotonin levels really to blame for depression? Probably not, according to an umbrella review of 17 studies. (Molecular Psychiatry)
There wasn’t an increase in methadone-involved overdose deaths in March 2020 following the implementation of take-home methadone doses as part of pandemic-era opioid treatment programs. However, there was a spike in overall drug overdose deaths at this time, largely driven by fentanyl. (JAMA Psychiatry)
The NeuroStar transcranial magnetic stimulation system earned a new indication and now is cleared for anxious depression, Neuronetics announced.
Researchers at the Children’s Hospital of Philadelphia created a new algorithm to parse out kids with attention deficit-hyperactivity disorder alone versus those with comorbidities, in hopes of gearing both groups toward more targeted treatment options.
An investigational alcohol use disorder (AUD) treatment failed to significantly reduce heavy drinking days in the phase III ONWARD trial, Adial Pharmaceuticals announced, but the company is touting a 79% reduction in drinking from baseline among the subgroup of heavy drinkers.
The National Institute for Health and Care Excellence in the U.K. released updated guidelines for the management of adult depression. Some updates include avoiding antidepressants as first-line treatment for less severe cases and using a proportional reduction schedule when stopping antidepressants. (The BMJ)
The FDA granted breakthrough device designation to Roche’s minimally invasive Alzheimer’s disease blood detector, the Elecsys Amyloid Plasma Panel.
A slew of employees in the psychiatric department at Harlem’s Metropolitan Hospital recently quit due to allegedly violent working conditions. (Gothamist)
Correction: An earlier version implied that the ONWARD trial met its primary endpoint.